On May 6, 2026 BeOne Medicines, a global oncology company, reported financial results and corporate updates from the first quarter of 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said:

"These strong first-quarter results reinforce BeOne’s continued growth as a global oncology leader, driven by disciplined commercial execution, and underpinned by our established hematology leadership, and an impressive, rapidly emerging solid tumor pipeline. The sustained competitive advantages of our global superhighway for clinical development and manufacturing are now clear. BRUKINSA has firmly established itself as the foundational, best-in-class BTK inhibitor with unmatched long-term efficacy and safety data for the treatment of CLL and as the only BTKi with proven efficacy superiority over ibrutinib which has resulted in clear global revenue leadership. The fixed-duration combination of sonrotoclax, a foundational, next-generation BCL2 inhibitor, and BRUKINSA represents a potential new standard-of-care in first-line CLL, with BTK CDAC BGB-16673 emerging as a potential first-in-class therapy in the relapsed or refractory setting. With more than 20 abstracts across our hematology and solid tumor pipeline accepted for presentation at ASCO (Free ASCO Whitepaper), BeOne has solidified its position as a leading oncology company."

(Press release, BeiGene, MAY 6, 2026, View Source [SID1234669166])

On May 6, 2026 Novo Nordisk reported financial report for the period 1 January 2026 to 31 March 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, Novo Nordisk, MAY 6, 2026, View Source [SID1234669137])

On May 6, 2026 BeOne Medicines reported first quarter 2026 results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, BeOne Medicines, MAY 6, 2026, View Source [SID1234666035])

On May 6, 2026 BeOne Medicines reported first quarter 2026 financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, BeOne Medicines, MAY 6, 2026, View Source [SID1234666034])

On May 6, 2026 Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, reported the discovery of the primary mechanism of action (MOA) of its lead oncology asset, (E,E)-bisantrene. Bisantrene has a long clinical history of activity across a range of cancer indications, but its mechanism of action has been unknown.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Preclinical studies undertaken by Racura and collaborators identified that (E,E)-bisantrene exerts its anticancer activity by binding to and stabilizing G-quadruplex (G4) DNA and RNA structures, key regulatory elements involved in controlling oncogene expression.

At the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, Racura presented new preclinical data demonstrating that (E,E)-bisantrene directly binds and stabilizes G4 DNA structures within the c-MYC gene promoter region, resulting in potent suppression of c-MYC expression and broad cytotoxic activity in a wide range of cancer models.[1][2]

The MYC protein functions as a master regulator of gene expression, governing thousands of genes involved in cell growth, differentiation, survival, metabolic reprogramming, chemotherapy resistance, and immune surveillance.[3] Crucially, MYC is the most commonly deregulated oncogene across human cancers, and has often been referred to as the ‘holy grail’ of targets due to its prevalence across many cancer indications. The promoter region of the c-MYC gene contains G4 DNA structures, which can suppress MYC expression when stabilized by drug binding.[4]

Race Oncology CEO and Managing Director, Dr Daniel Tillett said, "The discovery that (E,E)-bisantrene acts primarily by binding to G4-DNA structures leading to the inhibition of c-MYC expression fundamentally changes our thinking on how to best use this drug in the clinic.

This body of work significantly advances our understanding of (E,E)-bisantrene and highlights its potential as a best-in-class therapy targeting a central driver of cancer, MYC dysregulation."

(Press release, Racura Oncology, MAY 6, 2026, View Source [SID1234665239])